You are here

Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin

Company Anticipates Potential Market Launch by Early 2020 Company Anticipates Potential Market Launch by Early 2020
Tuesday, February 19, 2019 - 08:30